Induction of micronuclei in peripheral blood lymphocytes of patients treated for rheumatoid or osteo-arthritis of the knee with dysprosium-165 hydroxide macroaggregates or yttrium-90 silicate.
The advantages of radiation synovectomy, using preparations containing dysprosium-165 (Dy-165), over conventional materials based on yttrium-90 (Y-90) include a more ideal spectrum of decay energies, and a much shorter half-life permitting quicker and more efficient treatment. A new therapeutic agent, Dy-165 hydroxide macroaggregates, has been developed for the treatment of arthritis making use of these advantages. As part of a clinical trial of this material 42 patients were examined for micronucleus frequency in their peripheral blood lymphocytes prior to, and 2 weeks after, radiation synovectomy using Dy-165 hydroxide macroaggregates or Y-90 silicate. In the majority of patients from each treatment group no significant increase in micronucleus frequency was observed. This indicates that in these cases leakage of material from the site of treatment was not resulting in detectable irradiation of circulating cells irrespective of the choice of radiopharmaceutical. The maximum increase in micronucleus frequency observed corresponded to a radiation dose to circulating cells of approximately 0.3 Gray.
Biomedicine and Health Program, Australian Nuclear Science and Technology Organisation, Menai, NSW.
J S
JS
Prosser
B E
BE
Izard
J K
JK
Brown
E L
EL
Hetherington
R M
RM
Lambrecht
L
L
Cato
M
M
Wallace
J
J
Whitwell
J
J
Wiseman
R
R
Hoschl
D000328:Adult; D001172:Arthritis, Rheumatoid / Q000532:radiotherapy*; D004419:Dysprosium / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007719:Knee Joint / Q000528:radiation effects; D008214:Lymphocytes / Q000528:radiation effects*; D008297:Male; D048629:Micronuclei, Chromosome-Defective / Q000528:radiation effects*; D008875:Middle Aged; D010003:Osteoarthritis / Q000532:radiotherapy*; D011868:Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use*; D017640:Silicates; D012824:Silicic Acid / Q000009:adverse effects* / Q000627:therapeutic use; D013583:Synovial Membrane / Q000528:radiation effects; D015019:Yttrium / Q000009:adverse effects* / Q000627:therapeutic use
D011868:Radioisotopes; D017640:Silicates; D012824:Silicic Acid; D004419:Dysprosium; C028301:yttrium silicate; D015019:Yttrium